Trial Profile
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- 08 Dec 2020 Results of pooled analysis (CLL7, CLL8, CLL10, CLL11 and CLL2M)presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 14 Feb 2018 Status changed from active, no longer recruiting to completed.
- 29 Aug 2016 Results (N=554) of this and other trial (CLL8) published in the Journal of Clinical Oncology (2016).